Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? results of a placebo-controlled trial from the north central cancer treatment group (N05C4)

Aminah Jatoi, Abby Thrower, Jeff A Sloan, Patrick J. Flynn, Nicole Lee Wentworth-Hartung, Shaker R. Dakhil, Bassam I. Mattar, Daniel A. Nikcevich, Paul Novotny, Aleksandar D Sekulic, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose. Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes. Methods. This placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks. Results. Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreentreated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p =.20). Quality of life scores declined but remained comparable between arms. Conclusions. Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.

Original languageEnglish (US)
Pages (from-to)1016-1022
Number of pages7
JournalOncologist
Volume15
Issue number9
DOIs
StatePublished - 2010

Fingerprint

Sunscreening Agents
Exanthema
Epidermal Growth Factor Receptor
Placebos
Neoplasms
Therapeutics
Sun Protection Factor
Quality of Life
Solar System
Physicians

Keywords

  • EGFR
  • Placebo
  • Rash
  • Sunscreen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? results of a placebo-controlled trial from the north central cancer treatment group (N05C4). / Jatoi, Aminah; Thrower, Abby; Sloan, Jeff A; Flynn, Patrick J.; Wentworth-Hartung, Nicole Lee; Dakhil, Shaker R.; Mattar, Bassam I.; Nikcevich, Daniel A.; Novotny, Paul; Sekulic, Aleksandar D; Loprinzi, Charles Lawrence.

In: Oncologist, Vol. 15, No. 9, 2010, p. 1016-1022.

Research output: Contribution to journalArticle

Jatoi, Aminah ; Thrower, Abby ; Sloan, Jeff A ; Flynn, Patrick J. ; Wentworth-Hartung, Nicole Lee ; Dakhil, Shaker R. ; Mattar, Bassam I. ; Nikcevich, Daniel A. ; Novotny, Paul ; Sekulic, Aleksandar D ; Loprinzi, Charles Lawrence. / Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? results of a placebo-controlled trial from the north central cancer treatment group (N05C4). In: Oncologist. 2010 ; Vol. 15, No. 9. pp. 1016-1022.
@article{af330aa2339e415090f75e3c7ee65753,
title = "Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? results of a placebo-controlled trial from the north central cancer treatment group (N05C4)",
abstract = "Purpose. Rash occurs in >50{\%} of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes. Methods. This placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks. Results. Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78{\%}) and 39 (80{\%}) sunscreentreated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p =.20). Quality of life scores declined but remained comparable between arms. Conclusions. Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.",
keywords = "EGFR, Placebo, Rash, Sunscreen",
author = "Aminah Jatoi and Abby Thrower and Sloan, {Jeff A} and Flynn, {Patrick J.} and Wentworth-Hartung, {Nicole Lee} and Dakhil, {Shaker R.} and Mattar, {Bassam I.} and Nikcevich, {Daniel A.} and Paul Novotny and Sekulic, {Aleksandar D} and Loprinzi, {Charles Lawrence}",
year = "2010",
doi = "10.1634/theoncologist.2010-0082",
language = "English (US)",
volume = "15",
pages = "1016--1022",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? results of a placebo-controlled trial from the north central cancer treatment group (N05C4)

AU - Jatoi, Aminah

AU - Thrower, Abby

AU - Sloan, Jeff A

AU - Flynn, Patrick J.

AU - Wentworth-Hartung, Nicole Lee

AU - Dakhil, Shaker R.

AU - Mattar, Bassam I.

AU - Nikcevich, Daniel A.

AU - Novotny, Paul

AU - Sekulic, Aleksandar D

AU - Loprinzi, Charles Lawrence

PY - 2010

Y1 - 2010

N2 - Purpose. Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes. Methods. This placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks. Results. Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreentreated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p =.20). Quality of life scores declined but remained comparable between arms. Conclusions. Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.

AB - Purpose. Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes. Methods. This placebo-controlled, double-blinded trial enrolled rash-free patients starting an EGFR inhibitor. Patients were randomly assigned to sunscreen with a sun protection factor of 60 applied twice a day for 28 days versus placebo. They were then monitored for rash and quality of life (Skindex-16) during the 4-week intervention and for an additional 4 weeks. Results. Fifty-four patients received sunscreen, and 56 received placebo; the arms were balanced at baseline. During the 4-week intervention, physician-reported rash occurred in 38 (78%) and 39 (80%) sunscreentreated and placebo-exposed patients, respectively (p = 1.00); no significant differences in rash rates emerged over the additional 4 weeks. There were no significant differences in rash severity, and patient-reported outcomes of rash yielded similar conclusions. Adjustment for sun intensity by geographical zone, season, and use of photosensitivity medications did not yield a significant difference in rash across study arms (p =.20). Quality of life scores declined but remained comparable between arms. Conclusions. Sunscreen, as prescribed in this trial, did not prevent or attenuate EGFR inhibitor-induced rash.

KW - EGFR

KW - Placebo

KW - Rash

KW - Sunscreen

UR - http://www.scopus.com/inward/record.url?scp=77957818555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957818555&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0082

DO - 10.1634/theoncologist.2010-0082

M3 - Article

C2 - 20798191

AN - SCOPUS:77957818555

VL - 15

SP - 1016

EP - 1022

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -